Receptor Tyrosine Kinase

Receptor tyrosine kinases (RTKs) are the 58-member family of membrane receptors that transduce growth factors: an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular kinase that, when ligand dimerises the receptor, trans-phosphorylates its partner's tyrosines — creating the docking sites that assemble the RAS-ERK and PI3K-AKT pathways. EGFR/HER2, insulin receptor, VEGFR, FGFR, MET, KIT: the family runs development, metabolism, angiogenesis, and immunity — and mutated into constitutive signalling, it drives the majority of human cancers. RTK inhibitors are oncology's most-used targeted drugs.

Gene
EGFR, ERBB2–4, INS R, FGFR1–4, VEGFR1–3, MET, KIT, PDGFRA/B, ALK, RET…
Family
Receptor tyrosine kinases (20 subfamilies)
Location
Plasma membrane; some variants in nucleus
Structure
Extracellular ligand domain + TM helix + cytoplasmic Tyr kinase with regulatory juxtamembrane/C-tail
Binding Partners
Ligands (EGF, insulin, VEGF…), GRB2/SOS, PI3K p85, SHP2, PLCγ via SH2/PTB

Structure

Function

Regulation

Interactions

Clinical Relevance

Sources